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Background
Influenza viruses containing chimeric hemagglutinin
(HA) glycoproteins with large foreign polypeptide inser-
tions are being examined as a novel vaccine vectors. Our
initial studies involved polypeptide insertions derived
from the Bacillus anthracis protective antigen (PA), and
showed that the entire140 amino acid receptor binding
domain of PA could be incorporated into functional chi-
meric PA/HA proteins. These were engineered into infec-
tious influenza viruses by reverse genetics, and the
resulting viruses displayed replication properties similar
to WT influenza virus. Using a mouse model, we exam-
ined the induction of antibody responses using heterolo-
gous prime/boost strategies with a variety of PA vectors
(influenza, vaccinia, rabies, cDNA), and we found that
strategies involving initial priming with the influenza vec-
tor resulted in anti-PA serum antibody titers that were 10-
fold higher than alternative regimes. These sera displayed
in vitro neutralization titers against anthrax toxin that were
remarkably high, >10-fold greater than values considered
to be neutralization positive, and animal protection
experiments are currently underway.
Methods
Using similar strategies, chimeric HIV Env/influenza HA
proteins have been generated, functionally characterized,
incorporated into influenza viruses by reverse genetics,
analyzed for replication properties, and used as immuno-
gens.
Results
We have generated functional chimeric HA proteins with
insertions of the Env protein as large as 250 amino acids.
ELISA data suggest that some of these expressed chimeric
Env/HA glycoproteins can be recognized by the anti-Env
neutralizing antibodies 2G12 and 447-52D, and the chi-
meric proteins have been incorporated into influenza
viruses that replicate to titers within one log of WT influ-
enza. Inserts are stable upon passage, and will initially be
evaluated as immunogens in mice.
Conclusion
It is possible to generate efficiently replicating influenza
viruses with chimeric hemagglutinin proteins that contain
insertions of up to 250 residues of HIV Env proteins to
evaluate as vaccine candidates.
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